Conference Coverage
Conference Coverage
ALK inhibitor alectinib shows DFS benefit in early NSCLC
Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs. chemotherapy in resected stage IB-IIIA NSCLC....
Conference Coverage
Perioperative nivolumab improves EFS in resectable NSCLC
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs. neoadjuvant nivolumab plus...
Conference Coverage
ICIs improve pCR rates in early ER+/HER2– breast cancer
Nivolumab and pembrolizumab boosted pathologic complete response rates when added to neoadjuvant and adjuvant therapy in patients with high-risk...
Conference Coverage
Observation, not radiotherapy, after radical prostatectomy
The investigators observed no benefit to adjuvant radiotherapy after radical prostatectomy in patients with prostate cancer in the phase 3...
Conference Coverage
No benefit to adding ICI to chemo in triple-negative breast cancer: study
There were no differences in 5-year event-free survival among patients with TNBC who received neoadjuvant chemotherapy with or without...
Conference Coverage
Remote symptom monitoring in advanced cancer improves quality of life
Building on prior studies, a new trial shows that digital symptom monitoring during cancer treatment detects symptoms early, improves quality of...
Conference Coverage
Fasting during breast cancer chemo improves quality of life
Short-term fasting around the time of chemotherapy is a promising supportive therapy during breast cancer chemotherapy that may enhance quality of...
Conference Coverage
Does first-line pembrolizumab add-on improve PFS in high-risk cervical cancer?
An FDA decision is expected in January on pembrolizumab with concurrent chemoradiotherapy for the first-line treatment of locally advanced...
Conference Coverage
Can some patients with esophageal cancer avoid surgery?
About one-third of patients with esophageal cancer who have a compete response to neoadjuvant chemoradiotherapy may be able to avoid surgery....
Conference Coverage
Adjuvant abemaciclib-ET combo shows long-term benefit in high-risk early breast cancer
Invasive disease–free and distant recurrence–free survival were better with the CDK4/6 inhibitor plus endocrine therapy than endocrine therapy...
Conference Coverage
When to treat DLBCL with radiotherapy?
Choices depend on factors like evidence of disease, radiologists say.